Iron overload cardiomyopathy

Area of Science:

• Cardiology
• Hematology
• Toxicology

Background:

• Iron overload cardiomyopathy (IOC) is a significant cause of death in hereditary hemochromatosis and transfusion-dependent anemias.
• Excess iron saturates transferrin, leading to non-transferrin-bound iron, which enters cardiomyocytes and causes oxidative stress and cellular damage.
• This results in a spectrum of cardiac dysfunction, from diastolic impairment to heart failure and arrhythmias.

Purpose of the Study:

• To provide a comprehensive, evidence-based review of the pathophysiology, diagnosis, and management of iron overload cardiomyopathy.
• To highlight advancements in diagnostic tools and therapeutic strategies for IOC.

Main Methods:

• Review of current literature on iron metabolism, cardiac complications, and treatment modalities for IOC.
• Analysis of diagnostic techniques, including cardiac magnetic resonance T2*.
• Evaluation of therapeutic approaches, including phlebotomy, iron chelation, and emerging treatments.

Main Results:

• Cardiac magnetic resonance T2* has improved diagnosis and risk stratification, guiding chelation therapy and reducing cardiac mortality.
• Phlebotomy is standard for primary hemochromatosis; iron chelators (deferoxamine, deferiprone, deferasirox) are used for transfusion-dependent patients.
• Adjunctive amlodipine and novel disease-modifying therapies for underlying conditions show promise in managing myocardial iron.

Conclusions:

• Effective management of IOC relies on early diagnosis and tailored treatment strategies, including chelation therapy.
• Advances in treating underlying conditions like thalassemia may prevent or mitigate IOC.
• Continued research into novel therapies is crucial for improving outcomes in patients with iron overload cardiomyopathy.